IPF Catalyst Challenge recognizes Owlstone Medical’s Breath Biopsy platform
 

Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, today announced it is one of the three winners of the global Idiopathic Pulmonary Fibrosis (IPF) Catalyst Challenge, sharing the $1,000.000 (£720,000 GBP) award, each receiving $333,333 (£240,000 GBP).

More...